World Vaccine Congress Lyon 2012

In Partnering and Corporate strategy by Freya SmaleLeave a Comment

world vaccine congress lyon

Today marks the beginning of the World Vaccine Congress Lyon 2012.

What do the sponsors believe will be the future of the vaccine industry?

 

Expres2ion

ExpreS2ion Biotechnologies has developed a complete proprietary stable protein expression platform, ExpreS2, based on engineered Drosophila Schneider-2 (S2) cells, to serve recombinant protein production needs of research teams and recombinant subunit vaccine developers. ExpreS2ion Biotechnologies offers access to the ExpreS2 platform through licensing opportunities for use in R&D and commercial protein manufacturing. After successful evaluation, an R&D or commercial license can be procured.

The ExpreS2 platform comprises all the elements needed for robust, scalable and reliable protein production, adapted to the needs of medical research and development. The platform has been shown to perform very successful with proteins difficult to express in other systems and, as the platform is cGMP-compliant, it provides a seamless and easy to scale means of accelerating promising projects, from the laboratory to commercial manufacturing.

How do you see the demand for your product / service changing over the next 12 months?

Demand will increase as more companies are becoming aware of the advantages of our platform

What is the USP of your product / solution in relation to your peers?

Shorter timelines with lower capital investment and running costs than standard mammalian cell operations; better batch to batch consistency compared to BEVS and better product homogeneity; licensable commercial cell line, with support from an expert team.

How do you see your product / service changing the industry segment it is targeting?

Our technology enables "dead-end" projects and provides a lower cost alternative to recombinant subunit vaccine projects.

 

GE Healthcare

GE Healthcare is a $16-billion unit of the General Electric Company (NYSE:GE), employing more than 46,000 people worldwide. Our healthymagination program to address global healthcare needs and to make health sustainable, aims to help our customers provide healthcare at a lower cost, to more people, with improved quality. GE Healthcare Life Sciences supports customers with advanced technologies for efficient and flexible process development and manufacture of biopharmaceuticals – helping to shorten time-to-market, increase output, and assure quality. Our products are used upstream and downstream, for chromatography, filtration and disposable processing, and at all scales from laboratory to production.

How do you see the demand for your product / service changing over the next 12 months?

We are seeing an increased interest in our offering and this will likely continue in the next year as well.

What is the USP of your product / solution in relation to your peers?

We have an offering leveraging our core in bioprocessing, the size and the network we have as a company and a solution that will facilitate for the customer.

How do you see your product / service changing the industry segment it is targeting?

Our goal is to help local vaccine companies establish cost-effective facilities with high quality standards, thereby contributing to better health globally.

 

InDevR/ IUL Instruments

InDevR, Inc., a biotechnology company developing advanced life science instrumentation and assays for analysis of viruses and other microorganism.
IUL Instruments GmbH, Germany is the European Distributor for InDevR products with responsibility for Sales and Services

How do you see the demand for your product / service changing over the next 12 months?

Vaccine manufacturers utilize techniques that are very slow, labor intensive and old. The ViroCyt Virus Counter is a new and inexpensive method that can quantify intact virus particles in 10 minutes. We have seen increasing demand for this technology as customers are learning of its availability.

What is the USP of your product / solution in relation to your peers?

Today, there is no other product on the market which can quantify intact virus particles in such a short time with equivalent reproducibility and accuracy.

How do you see your product / service changing the industry segment it is targeting?

Ultimately, vaccines will be on the market faster, cheaper and with improved quality control.

 

ITS

Immune Targeting Systems (ITS) is a London based biotech company developing vaccines for mutating viruses underpinned by its DepoVaccine and High Density Antigen identification technology platforms. ITS's lead program is a synthetic universal influenza vaccine targeting all potential seasonal and pandemic flu strains. A clinical trial application was submitted to the UK MHRA in July 2010 and clinical testing is expected to start in Q3-2010. Lead-optimisation has commenced on a universal Hepatitis-B therapeutic vaccine (genotypes A,B,C,D & Other).

DepoVaccines deliver high density antigens to the immune system and promote a vaccine depot at the injection site. This depot promotes potent, durable and recallable antiviral T-cell immunity without adjuvants. Vaccine design and antigen selection specifically address key aspects of human immunological-vaccine performance required for clinical success; (i) vaccine responder frequency >95%, (ii) breadth of response, (iii) magnitude of response, & (iv) multi-re-use capability afforded by synthetic long-peptides.

How do you see the demand for your product / service changing over the next 12 months?

We anticipate that the demand for our product will be driven by the need to address the current and significant problems with conventional influenza vaccine, and its shortfall in efficacy to seasonal influenza, particularly in at risk populations, and its inherent inability to manage pandemic outbreaks.

What is the USP of your product / solution in relation to your peers?

The USP of our product is its ability to induce a pan influenza A immune response targeting multiple/all influenza A strains of virus (seasonal and pandemic). Through its ability to mobilise a cross protective cell mediated immune response it can be used in a variety of ways including in combination with conventional influenza vaccine to improve efficacy in at risk populations (e.g. older adults) and be stockpiled in preparedness for pandemic outbreaks.

How do you see your product / service changing the industry segment it is targeting?

Our vaccine will have an impact on the out dated paradigm of relying solely on the mobilisation of a restricted specific antibody response to manage influenza infection, and incorporate the cell mediated response which is better equipped to manage strain drifts and shifts.  The net benefit will be a significant improvement in vaccine efficacy and reduction in spread, morbidity and mortality caused by seasonal and pandemic influenza.

 

LabCorp

Labcorp Clinical Trials combines standardized international laboratory capabilities with sophisticated diagnostic technologies to provide a broad portfolio of clinical assays to support drug and diagnostic clinical studies. We have four dedicated central lab facilities located in China, Belgium, Singapore, and the United States. Our scientific team, with expertise across major therapeutic areas, provides extensive support for protocol design and custom assay development. An experienced operations team delivers focused project management and investigator services, and our global data management system provides single study set-up mechanism.

How do you see the demand for your product / service changing over the next 12 months?
We expect to see a greater demand for a single provider for truly global PBMC isolation services which will avoid the traditional quality and standardization challenges from multiple providers.

What is the USP of your product / solution in relation to your peers?
LabCorp Clinical Trials PBMC Network's Unique Selling Point is that we are still the only single entity to offer a global network for standardized PBMC isolation services and that our coverage areas continue to expand across the world.

How do you see your product / service changing the industry segment it is targeting?
With greater access to a single global provider of quality and standardized PBMC isolation service, our industry clients will benefit from higher and more useful yields of viable PBMCs for their vaccine, oncology and other Clinical Trial and research projects.

 

Retroscreen

Retroscreen Virology is Europe's leading specialist virology contract research organization (CRO). The work we conduct is dedicated to creating the next generation of antivirals and vaccines for a number of respiratory and enteric viral diseases. Our research includes preclinical laboratory-based services and Phase Ib/ IIa clinical services based on the human viral challenge model.

Experimental challenge studies, where healthy volunteers are infected with virus so that novel antivirals and vaccines can be assessed in a controlled manner, can rapidly reduce the time and cost of drug development by accelerating the selection of safe and effective dose and dosing regimes. These studies are routinely performed in Retroscreen's purpose-built, specifically designed 24-bed quarantine facility.

We currently conduct and co-ordinate several clinical trials per year particularly involving influenza, RSV or common cold viruses. Please contact us or browse our website for more information.

How do you see the demand for your product / service changing over the next 12 months?

We expect to see the current high demand continue, and possibly increase over the next 12 months

What is the USP of your product / solution in relation to your peers?

We are the only commercial company routinely conducting human viral challenge studies

How do you see your product / service changing the industry segment it is targeting?

The challenge model offers a unique and cost-effective solution for accelerated proof-of-concept for vaccines and new anti-virals, avoiding the need for more extensive and costly field-based trials

 

Vibalogics

Vibalogics supports innovative companies which are developing vaccines, gene therapeutics or virotherapeutics. We work with live viruses and bacteria and offer process development, GMP-manufacturing, analytical testing and fill & finish.
In addition we generate and select expression vectors based on Pichia pastoris, one of the most promising expression hosts for vaccines based on virus-like particles (VLP).

How do you see the demand for your product / service changing over the next 12 months?

As a service provider we currently see rising demand for process development and GMP production for live bacterial and viral vaccines. This includes prophylactic and therapeutic vaccine types and also oncolytic viruses. As these products are frequently associated with a complex biology and challenging to produce, our clients look for CMOs with highly experienced operators supported by QC/QA with adequate expertise.

What is the USP of your product / solution in relation to your peers?

· High quality and modern multi-product facility

· Experts in the field of live bacterial/viral vaccine and viral gene vector and oncolytic viruses (BSL-2)

· From proof-of-principle/concept studies to clinical trial material including Fill & Finish and QP release

· Professional Project Management team in place including PMP/PMI certification

How do you see your product / service changing the industry segment it is targeting?

· Development of platform technologies shall enable plug-and-play approaches to cut time lines, budget and secure process and production success

· With our professional and pro-active approach we can positively influence client's timelines and budget. Time to clinic is crucial for most clients and we support this target all the way to the finish-line

· With the end product on mind, we guide our clients from start-to-finish minimizing thereby risks and failure probability

 

To find out more about the future of the vaccine industry, stay tuned! Exclusive live feed from the event available here.

For more updates on the vaccines industry, follow us on Twitter:  @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *